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ORIGINAL ARTICLEFirst report of mecC MRSA in human samples from Austria: molecular
characteristics and clinical dataH. Kerschner1, E. M. Harrison2, R. Hartl1, M. A. Holmes2 and P. Apfalter1
1) National Reference Center for Antimicrobial Resistance and Nosocomial Infections, Institute for Hygiene, Microbiology and Tropical Medicine, Elisabethinen
Hospital, Linz, Austria and 2) Department of Veterinary Medicine, University of Cambridge, Cambridge, United KingdomAbstractReports of mecC methicillin-resistant Staphylococcus aureus (MRSA) strains have been published from several European countries. We
describe the ﬁrst six mecC MRSA isolates of human origin from Austria and report the application of a rapid PCR test. Candidate isolates
(n = 295) received between 2009 and 2013 were investigated phenotypically by cefoxitin screening and streaking on ChromID MRSA
plates. The presence of mecC was conﬁrmed in six isolates from blood cultures, wound swabs and screening samples of four female and
two male patients (age range 7–89 years) by an in-house PCR method and the new Genspeed MRSA test (Greiner Bio-One,
Kremsmünster, Austria). The mecC MRSA were further characterized by whole genome sequencing, multilocus sequence and spa typing.
Antimicrobial susceptibility testing was performed by Eucast disk-diffusion method and Vitek 2. The six mecC MRSA isolates were from
two clonal lineages (CC130, including a new single-locus variant, and CC599) and four different spa types (t843, t1535, t3256, t5930).
Analysis for virulence factor genes yielded lukED, eta, etd2 and edin-B (CC130 isolates) and tst, lukED, eta and sel (ST599 isolates). The
Genspeed MRSA test identiﬁed mecC in all isolates whereas Vitek 2 failed to detect methicillin resistance in one isolate. The strains were
susceptible to a wide range of non-β-lactam antibiotics. All patients were successfully treated or decolonized. mecC MRSA are present in
Austria as colonizers but may also cause infections. Thus, laboratories must choose appropriate test methods such as cefoxitin screening
and conﬁrmation using molecular assays speciﬁcally targeting mecC.
New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: petra.apfalter@analyse.euIntroductionMethicillin-resistant Staphylococcus aureus (MRSA) isolates car-
rying the mecA homologue mecC have been reported from all
over Europe [1–8]. They may be detected phenotypically by
routine cefoxitin screening and by PCR using speciﬁc primers;
however, standard molecular diagnostic systems based onw Microbe and New Infect 2015; 3: 4–9
w Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
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p://dx.doi.org/10.1016/j.nmni.2014.11.001ampliﬁcation of mecA fail to recognize these strains due to
nucleic acid divergences between mecA and mecC. Published
clinical data concerning mecC MRSA in humans include reports
about colonization as well as skin and soft tissue infections [4],
but also include fatal bacteremia [7] and osteomyelitis [9]. Thus,
reliable detection of these strains in diagnostic microbiology
routine is important [10].
The National Reference Centre for Antimicrobial Resistance
and Nosocomial Infections at the Elisabethinen Hospital Linz
receives bacterial isolates of human origin for identiﬁcation,
conﬁrmation and typing from Austrian laboratories. Its strain
collection contains over 5000 isolates of Staphylococcus spp.
many of which have been extensively studied and typed using
molecular methods [11–14]. We searched this strain collection
for S. aureus carrying mecC using the conventional phenotypicEuropean Society of Clinical Microbiology and Infectious Diseases.
.0/)
NMNI Kerschner et al. mecC MRSA in Austria 5approach followed by molecular conﬁrmation with an in-house
PCR method as well as one of the ﬁrst commercially available
systems also able to detect mecC, the Genspeed MRSA test
(Greiner Bio-One, Kremsmünster, Austria). In addition, clinical
and molecular typing data on four mecC-positive isolates
detected as part of routine screening are presented, describing
for the ﬁrst time the presence of mecC MRSA in human samples
from Austria.Materials and MethodsBacterial isolates, phenotypic and molecular antibiotic
susceptibility testing and typing
Candidate S. aureus isolates (n = 295) that had tested negative
for mecA and positive for femA using previously published
primer sets between the years 2003 and 2012 were chosen
from the strain collection [15,16]. Additionally, four strains
received from Austrian laboratories in 2012–2013 for further
testing regarding mecC were included in this study. Strains were
subcultured overnight on trypticase soy agar containing 5%
sheep’s blood (Oxoid, Wesel, Germany) at 36 ± 1°C in anTABLE 1. Phenotypic and molecular typing data of six mecC methi
Isolate 4402/2009 Isolate 5127/2010 Isolate 5590
Disk diffusion test
Diameter (mm)
(category)
Diameter (mm)
(category)
Diameter (
(category)
Cefoxitin 18 (mean, R) 16 (mean, R) 21 (mean, R)
Gentamicin 20 (S) 22 (S) 20 (S)
Erythromycin 26 (S) 26 (S) 24 (S)
Clindamycin 25 (S) 26 (S) 22 (S)
Tetracycline 25 (S) 26 (S) 22 (S)
Fusidic acid 30 (S) 31 (S) 26 (S)
Trimethoprim/sulfa 32 (S) 31 (S) 26 (S)
Rifampicin 31 (S) 30 (S) 27 (S)
Gradient MIC test MIC (mg/L) MIC (mg/L) MIC (mg/L
Ceftaroline 1 (S) 1 (S) 1 (S)
Vancomycin 1 (S) 1 (S) 2 (S)
Teicoplanin 1 (S) 1 (S) 2 (S)
Tigecycline 0.25 (S) 0.25 (S) 0.25 (S)
Linezolid 0.5 (S) 0.5 (S) 1 (S)
Daptomycin 0.25 (S) 0.125 (S) 0.125 (S)
Fosfomycin 1 (S) 1 (S) 0.5 (S)
Oxacillin 4 4 2
Cefoxitin 16 32 16
Typing
Multilocus sequence 599 130 SLV of 130
Type
Clonal complex 599 130 130
spa Type t5930 t3256 t1535
Virulence factor gene
tst + − −
lukED + + +
eta + + +
etd2 − + +
edin-B − + +
sel + − −
SLV, single locus variant; MIC, minimum inhibitory concentration.
New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on be
This is an oaerobic atmosphere. Species identiﬁcation of all isolates was
done by matrix-assisted laser desorption-ionization time-of-
ﬂight (MALDI-TOF) mass spectrometry using the IVD MALDI
Biotyper (Bruker Daltonik, Bremen, Germany) and the Vitek 2
system (bioMérieux, Marcy l’Etoile, France).
Susceptibility testing was performed according to the Eucast
disk-diffusion method. All strains were screened phenotypically
for methicillin susceptibility using cefoxitin 30 μg disks in quin-
tuplicate. They were also inoculated onto ChromID MRSA agar
plates (bioMérieux) that were read after 24 hours of incubation
at 37°C. The broader antimicrobial susceptibility of mecC MRSA
for a panel of substances (Table 1) was assessed by disk diffusion
testing, and for selected substances, minimum inhibitory con-
centrations (MICs) were determined by gradient diffusion
testing (Etest; bioMérieux) (Table 1). The susceptibility proﬁles
of the mecC MRSA were also assessed using Vitek 2 Gram-
positive antimicrobial susceptibility testing cards (bioMérieux).
All isolates showing a mean cefoxitin zone diameter <22 mm
and/or growth on selective media underwent conﬁrmatory
PCR testing using a protocol published by Stegger et al. [17] to
detect mecA, mecC and lukF-PV after extraction of bacterial
DNA with InstaGene Matrix (BioRad, Hercules, CA, USA), withcillin-resistant Staphylococcus aureus isolates
/2012 Isolate 5625/2012 Isolate 5676/2012 Isolate 5752/2013
mm) Diameter (mm)
(category)
Diameter (mm)
(category)
Diameter (mm)
(category)
18 (mean, R) 17 (mean, R) 20 (mean, R)
22 (S) 24 (S) 22 (S)
28 (S) 30 (S) 30 (S)
26 (S) 30 (S) 30 (S)
27 (S) 25 (S) 30 (S)
30 (S) 30 (S) 30 (S)
34 (S) 30 (S) 30 (S)
32 (S) 30 (S) 30 (S)
) MIC (mg/L) MIC (mg/L) MIC (mg/L)
1 (S) 0.5 (S) 0.5 (S)
1 (S) 1 (S) 2 (S)
1 (S) 1 (S) 0.25 (S)
0.25 (S) 0.125 (S) 0.25 (S)
0.5 (S) 0.5 (S) 2 (S)
0.125 (S) 0.25 (S) 0.25 (S)
1 (S) 0.5 (S) 2 (S)
8 4 2
16 32 16
130 599 130
130 599 130
t1535 t5930 t843
− + −
+ + +
+ + +
+ − +
+ − +
− + −
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6 New Microbes and New Infections, Volume 3 Number C, January 2015 NMNImodiﬁed primer concentrations. Additionally, a commercially
available rapid PCR system, the Genspeed MRSA (Greiner Bio-
One, Kremsmünster, Austria) was evaluated. This system uses
rapid bacterial lysis followed by conventional PCR and detec-
tion of mecA and mecC, including speciﬁc probes for S. aureus,
via hybridization on a chip.
Isolates carrying mecC were further analyzed by pulsed-ﬁeld
gel electrophoresis of SmaI restriction fragments. They were
also typed by ampliﬁcation of the polymorphic X region of the
protein A gene (spa) followed by sequencing and assignation of
the spa type [18]. Whole genome sequencing of mecC-positive
isolates was performed as previously described [19] to
conﬁrm their mecC gene status, to determine their multilocus
sequence type (ST) and to identify virulence factor and anti-
biotic resistance genes. Nucleotide sequences have been
deposited in the European short-read archive as ERR387183,
ERR387184, ERR387185, ERR387090, ERR 490434 and
ERR490433 for isolates 4402, 5127, 5590, 5625, 5675 and
5752, respectively.
Clinical information
Clinical information on patients with mecC MRSA was obtained
from medical records retrospectively. Consent of the local
ethics committee was provided (C-60-13).ResultsAll strains were conﬁrmed as Staphylococcus aureus with
MALDI-TOF scores of >2.0. Phenotypic screening of the 295
isolates from the strain collection revealed two cefoxitin
screening–positive isolates (0.7%) with mean diameters of 14
mm (range 13–14 mm) and 15 mm (all 15 mm), respectively.
Fourteen isolates (4.7%), including the two that were cefoxitin
screening positive, showed growth on ChromID MRSA agar.
Cefoxitin diameters of the other 12 isolates were in the sus-
ceptible category (range 27–32 mm); thus, sensitivity of the
ChromID MRSA agar for phenotypic methicillin resistance
detection was 100% and speciﬁcity was 95.9%.
Further analysis by molecular testing was performed on
these fourteen isolates. The two cefoxitin-resistant isolates
were positive for mecC and negative for mecA by conventional
PCR as well as with the new Genspeed MRSA test. In accor-
dance with their susceptibility to cefoxitin, the other 12 isolates
carried neither mecA nor mecC. Additionally, the four strains
that were received in our capacity as reference laboratory were
analyzed. All four isolates had a positive cefoxitin screening test
with diameters of 17, 18, 20 and 21 mm, respectively. Presence
of mecC and absence of mecA was conﬁrmed with both PCR
assays, and lukF-PV was not detected in any of the strains.New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3Analysis of spa sequencing data showed four different spa
types among the six isolates: t5930 (n = 2), t1535 (n = 2), t843
(n = 1) and t3256 (n = 1). Whole genome sequencing of all
isolates conﬁrmed that each isolate encoded mecC within an
SCCmec type XI. Sequence types derived from the genome
sequences included three ST130, a single-locus variant of ST130
and two ST599. All six isolates were positive for the genes
encoding leukocidin ED (lukED) (GenBank accession no.
Y13225) and exfoliative toxin A (eta) (GenBank accession no.
CAQ49592). The four isolates belonging to CC130 additionally
carried the epidermal cell differentiation inhibitor B gene (edin-B)
(GenBank accession no. AHC54577) and the exfoliative toxin D
gene (etd2) (GenBank accession no. HF563069). The two ST599
isolates were also positive for the toxic shock syndrome toxin-1
(tst) (GenBank accession no. Q9F0L4) and the enterotoxin-L
(sel) gene (GenBank accession no. CAI80052) (Table 1). Other
than mecC and blaZ, no other acquired resistance genes were
identiﬁed.
Analysis of SmaI pulsed-ﬁeld gel electrophoresis patterns
showed the strains to be unrelated, with the exception of iso-
lates 5590/2012 and 5625/2012, which were isolated in the same
area of Austria within 8 weeks of each other. The Dice coefﬁ-
cient for this pair was 85.9%, indicating possible relatedness.
Subsequently, the six mecC MRSA were subjected to anti-
microbial susceptibility testing and yielded susceptible results
for all non-β-lactam antibiotics (Table 1). Two isolates (5127/
2010 and 5752/2013) had oxacillin MICs below the breakpoint
usually used to infer methicillin resistance. Vitek 2 identiﬁed all
six isolates correctly as S. aureus and gave a positive result for
the cefoxitin screen in ﬁve isolates, whereas all isolates were
given a susceptible result for oxacillin. One isolate (5752/2013)
was identiﬁed as methicillin-susceptible Staphylococcus aureus
(MSSA) with a negative cefoxitin screen also upon repetition of
the test. The remaining susceptibility data of the AST GP card
matched the results of manual testing.
Clinical data are summarized in Table 2, and the geographic
location of the laboratories that provided the mecC MRSA
strains as well as the year of detection are indicated in Fig. 1.DiscussionTo our knowledge, this is the ﬁrst report concerning the
detection of mecC MRSA in humans in Austria. We can conﬁrm
the presence of such strains back to the year 2009 resulting
from the investigation of our strain collection. The only other
data on mecC MRSA in Austria covers livestock- and wildlife-
origin strains [20,21].
All mecC-positive isolates in this study were phenotypically
recognizable as MRSA using cefoxitin in the Eucast disk-European Society of Clinical Microbiology and Infectious Diseases, NMNI, 3, 4–9.
.0/)
TABLE 2. Clinical information of six mecC methicillin-resistant Staphylococcus aureus isolates
Characteristic Isolate 4402/2009 Isolate 5127/2010 Isolate 5590/2012 Isolate 5625/2012 Isolate 5676/2012 Isolate 5752/2013
Patient age/sex 89/female 54/female 7/female 72/female 83/male 70/male
Site of isolation Blood culture Multisite screen Wound swab (outer ear) Wound swab (leg ulcer) Nose screen Blood culture
Underlying disease Myelodysplastic
syndrome, sepsis
Diabetes, Eczema Otitis externa Ulcus cruris Stroke Peripheral arterial
occlusion disease,
infected leg ulcer
Therapy Unknown Octenidine/mupirocin Topical oﬂoxacin Topical silver-sulfa-diazine/
povidone-iodine
Mupirocin Clindamycin iv
Outcome Recovered Eradication Recovered Improvement Eradication Recovered
Risk factors Unknown Unknown Pet rabbit (not screened) Unknown Unknown Unknown
Geographic location Upper Austria Vienna Vorarlberg Vorarlberg Salzburg Upper Austria
No contact could be established between patients.
NMNI Kerschner et al. mecC MRSA in Austria 7diffusion test, which has been shown to reliably detect these
strains [22]. However, the built-in cefoxitin screen of the Vitek
2 GP AST card detected only ﬁve of the six isolates, which is in
contrast to a recent study using the same system successfully
on 62 mecC MRSA isolates [23]. However, the atypical Vitek 2
oxacillin-susceptible/cefoxitin-resistant proﬁle of mecC MRSA
as described by Cartwright et al. [23] was observed in the
remaining ﬁve isolates. Isolate 5752/2013, which was mis-
identiﬁed as MSSA by Vitek 2, had the largest cefoxitin diameter
(21 mm) of all isolates and thus was also challenging for disk-
diffusion test reading. All isolates were universally susceptible
to non-β-lactam antibiotics, which compares to data on mecC
MRSA from other European countries [6,7,24].
Previous reports have shown reduced efﬁciency of growth
on commercially available selective chromogenic media, also
including ChromID agar [6], for ST130 mecC MRSA. In contrast,FIG. 1. Location and year of isolation of six mecC methicillin-resistant Staphylo
is a public domain ﬁle downloaded from http://www.mygeo.info/karten/austri
New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on be
This is an oin our small sample also containing ST130 strains, all isolates
grew well on ChromID agar. However, the cefoxitin MICs of
our isolates were considerably higher than those reported by
Cuny et al. [6] (all 16 mg/L). The published cefoxitin content
of this medium is 4 mg/L [25,26], so efﬁcient growth was not
unexpected. Also, the observed false-positive rate of 4.1% is in
line with published data [27].
Up to now, PCR methods for MRSA detection have suc-
cessfully covered all known SCCmec types as a result of the
high homology of the mecA gene. However, the newly discov-
ered mecC element shares only 69% identity of its DNA
sequence with mecA, leading to negative results using mecA-
based PCR protocols and a need for additional primers to
detect mecC. At the moment, not all commercially available
assays cover this requirement. The Genspeed MRSA test that
we used in this study can be completed in 75 minutes fromcoccus aureus isolates. Most patients lived in rural areas of Austria. (Map
a_pol99.jpg.)
half of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 3, 4–9.
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8 New Microbes and New Infections, Volume 3 Number C, January 2015 NMNIculture; it can also be performed directly from swabs. It may be
used as screening tool for colonization with S. aureus (MSSA) as
well as mecA or mecC MRSA.
Four of the six mecC MRSA in our study belonged to CC130,
which agrees with previously published data from other coun-
tries that also show CC130 to be predominant [1,2,7,17,24].
Analysis of whole genome sequences of six strains revealed that
the CC130 isolates lacked pyrogenic toxin superantigen
(PTSAg) encoding genes, such as the toxic shock toxin gene tst
and staphylococcal enterotoxin genes. However they were all
positive for exfoliative toxin genes (eta and edinB). The occur-
rence of mecC in MRSA isolates belonging to ST599 is relatively
uncommon, but the two isolates in our study were positive for
the PTSAg genes tst and sel, which matches the toxin gene
proﬁle of previously published ST599 mecC MRSA isolates
[5,28]. Four different spa types were recovered in this study, all
of which have previously been reported among mecC MRSA.
t843 was the dominant spa type of mecC MRSA in a range of
reports [4,7,17] and spa types t1535 and t3256 have also been
described [7,24], whereas t5930 has so far only been
mentioned in a single report from France [5].
The capability of mecC MRSA to cause clinical disease in a
wide range of patients has been established by several reports.
In a Spanish case series, most patients were elderly men who
were colonized, but a patient with lethal sepsis was also
described [7]. Petersen et al. [4] reported on 112 mecC MRSA
isolates from Denmark, with equal sex distribution and a mean
patient age of 51 years. Interestingly, the majority of the isolates
were from infections, mostly skin and soft tissue infection, and
not from colonization screening. In a recent report on the
prevalence of human mecC MRSA in England, more than half of
the isolates were identiﬁed from screening samples [24],
whereas in a case series from Germany, most strains were
isolated from wounds but also included was an isolate from
nosocomial pneumonia [6]. A French case report described a
patient with mediastinitis and sternal osteitis due to mecC
MRSA [9]. In two of our six clinically diverse study patients,
mecC MRSA were identiﬁed via routine screening, but in the
remaining four patients, it was clearly associated with their
clinical presentation.
Overall, mecC MRSA do not seem to be highly prevalent in
Austria at the moment, which reﬂects the situation in most
other European countries [10]. On the other hand, the fre-
quency of mecC MRSA has increased signiﬁcantly to a propor-
tion of 2% of the total annual human MRSA cases in Denmark
[4]. As mecC is carried on a mobile genetic element (SCCmec),
it has the potential to spread into different lineages [29–31].
Thus, reliable detection and monitoring of mecC MRSA with
appropriate phenotypic and molecular screening and conﬁr-
mation methods is needed.New Microbes and New Infections © 2014 The Authors. Published by Elsevier Ltd on behalf of
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